Therapeutic Response Statement (Sensitivity)

This therapeutic response statement Supports the relationship that CD20 + status confers therapeutic sensitivity to Cyclophosphamide, Prednisolone, Rituximab, Vincristine in patients with Non-Hodgkin Lymphoma.

The Republic of Ireland's Health Service Executive (HSE) has approved cyclophosphamide in combination with prednisolone and vincristine for reimbursement as a treatment option for the first line treatment of patients with low grade B cell Non Hodgkin's Lymphoma (NHL). The regimen states that rituximab is to be included for the treatment of CD20 positive patients.

This statement is based on a regulatory approval from the Health Service Executive:

First line treatment of patients with low grade B cell Non Hodgkin's lymphoma (NHL). Rituximab to be included in CD20 positive patients.

Citation

riTUXimab, Cyclophosphamide, vinCRIStine and prednisoLONE R-CVP Therapy-21 days, 2023, version number 3a, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://assets.hse.ie/media/documents/293_v3a_R_CVP.pdf

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2017-03-08	Health Service Executive	Indication approved for reimbursement.